Artiva Biotherapeutics, Inc.ARTV财报
Nasdaq
Artiva Biotherapeutics是一家处于临床阶段的生物技术企业，专注开发现货型自然杀伤（NK）细胞疗法，用于治疗各类癌症与自身免疫性疾病，管线覆盖血液恶性肿瘤和实体瘤，致力于为未被满足的临床需求提供可及的有效免疫治疗方案。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| RA Capital Management, L.P. | 40.60% | 9.9M | ▼ -1.70pp | 2024-09-03 |
| GC Corp. | 19.60% | 4.6M | — | 2024-07-29 |
| Venrock Healthcare Capital Partners III, L.P. | 6.90% | 1.6M | — | 2024-08-01 |
| venBio Global Strategic Fund III, L.P. | 6.30% | 1.5M | ▼ -1.50pp | 2024-11-14 |
| Andrew J. Schwab | 5.00% | 1.2M | — | 2024-08-01 |
内部人交易
Net 90d: +$0 · buys $0 / sells $0时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-03-10 | Huston Thad Allen | Chief Financial Officer | Grant | 220.0K | $0.00 | $0 |
| 2026-02-15 | Subhashis Banerjee | Chief Medical Officer | Grant | 102.0K | $0.00 | $0 |
| 2026-02-15 | Jennifer Bush | COO, CLO, Secy, Compliance Off | Grant | 117.3K | $0.00 | $0 |
| 2026-02-15 | Heather Raymon | SVP, Research and Development | Grant | 46.0K | $0.00 | $0 |
| 2026-02-15 | Christopher Horan | Chief Tech Operations Officer | Grant | 117.3K | $0.00 | $0 |
| 2026-02-15 | Fred Aslan | President and CEO | Grant | 366.9K | $0.00 | $0 |
1–6 of 6